CGEM (Cullinan Oncology) Earnings per share for the last four quarters

Public company logo of Cullinan Oncology (CGEM)

The share price of Cullinan Therapeutics (CGEM) visualized below, where the EPS is 10.40, correlates with the company's focus on developing selective anti-tumor agents and licensing fees. The current financial status is based on the depletion of existing reserves to fund costly trials. However, geopolitical tensions and trade barriers could hinder the international certification of technologies and the procurement of necessary components.

CGEM cullinanoncology.com Earnings per share for the last twelve months (02/11/2024 - 11/18/2026)

Cullinan Oncology - analytical breakdowns and key metrics (CGEM)

Signature product of Cullinan Therapeutics, Inc.

Fundamental asset selection is based on profit dynamics analysis to assess business sustainability. This indicator measures the annual change in earnings per share over a rolling period, identifying growth rates or declines in capital efficiency. For Cullinan Therapeutics (CGEM), which generates no revenue due to the clinical status of its developments, this metric reflects only the dynamics of operating losses. Evaluate these fluctuations using the EPS YoY TTM relative change chart.

Competitor analysis for Cullinan Therapeutics

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ideayabio.com|Earnings per share for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics Inc)|Net earnings per share for the trailing year Nurix Pharma|Tyra Biosciences Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX